- Conditions
- Primary Dysmenorrhea
- Interventions
- high dose KYG0395, lower dose KYG0395, Placebo
- Drug
- Lead sponsor
- Jiangsu Kanion Pharmaceutical Co., Ltd
- Industry
- Eligibility
- 18 Years to 35 Years · Female only
- Enrollment
- 280 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2015
- U.S. locations
- 23
- States / cities
- Phoenix, Arizona • Little Rock, Arkansas • San Diego, California + 20 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 577–600
of 17,839
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Methamphetamine Use Disorder, Human Immunodeficiency Virus (HIV)
- Interventions
- Psilocybin 5 mg, Psilocybin 25 mg, Motivational Support
- Drug · Behavioral
- Lead sponsor
- Nicky Mehtani, MD, MPH
- Other
- Eligibility
- 25 Years to 64 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2029
- U.S. locations
- 1
- States / cities
- San Francisco, California
- Conditions
- Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma, Acute Lymphoblastic Leukemia, Diffuse Large B Cell Lymphoma, Triple Negative Breast Cancer Malignancies
- Interventions
- Fludarabine, Cyclophosphamide, PRGN-3007
- Drug · Biological
- Lead sponsor
- H. Lee Moffitt Cancer Center and Research Institute
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 3 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- Tampa, Florida
- Conditions
- Atrial Fibrillation
- Interventions
- Liraglutide, RFM, Anti Arrhythmics, Afib Catheter Ablation
- Drug · Other · Procedure
- Lead sponsor
- University of Miami
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 60 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Miami, Florida
- Conditions
- Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer
- Interventions
- Melphalan
- Drug
- Lead sponsor
- OHSU Knight Cancer Institute
- Other
- Eligibility
- 18 Years to 120 Years
- Enrollment
- 21 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2016
- U.S. locations
- 1
- States / cities
- Portland, Oregon
- Conditions
- Lymphoma
- Interventions
- filgrastim, recombinant interferon alfa, dexamethasone, melphalan, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- Up to 69 Years
- Enrollment
- 9 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1998 – 2004
- U.S. locations
- 84
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 55 more
- Conditions
- Hematologic Malignancy, Leukemia, Lymphoma, Lymphoma, B-Cell, Lymphoma, T-Cell, Lymphoma, Non-Hodgkin
- Interventions
- CAR-37 T cells
- Biological
- Lead sponsor
- Marcela V. Maus, M.D.,Ph.D.
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2024
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Cutaneous Tumor, Malignant Solid Tumor
- Interventions
- JCXH-211
- Drug
- Lead sponsor
- Immorna Biotherapeutics, Inc.
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 1 participant
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2023
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Healthy Volunteer
- Interventions
- Litifilimab, AI, OBI, PFS
- Drug · Device
- Lead sponsor
- Biogen
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 404 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 2
- States / cities
- Las Vegas, Nevada • Austin, Texas
- Conditions
- Prostate Cancer
- Interventions
- 16 French Foley Catheter
- Device
- Lead sponsor
- University of Alabama at Birmingham
- Other
- Eligibility
- 19 Years and older · Male only
- Enrollment
- 5 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- Birmingham, Alabama
- Conditions
- Cleft Palate
- Interventions
- Oral acetaminophen, Ofirmev®, Opioid only
- Drug
- Lead sponsor
- Loma Linda University
- Other
- Eligibility
- 5 Months to 5 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2014
- U.S. locations
- 1
- States / cities
- Loma Linda, California
- Conditions
- Healthy Volunteer
- Interventions
- ABBV-8736, Placebo
- Drug
- Lead sponsor
- AbbVie
- Industry
- Eligibility
- 18 Years to 55 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Grayslake, Illinois
- Conditions
- Cancer
- Interventions
- Birinapant
- Drug
- Lead sponsor
- TetraLogic Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 176 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 7
- States / cities
- Fort Lauderdale, Florida • Detroit, Michigan • Buffalo, New York + 3 more
- Conditions
- Hypertension (HTN), Hypertension
- Interventions
- Arugula Extract, Psyllium Husk
- Dietary Supplement
- Lead sponsor
- Baylor University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 16 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2025 – 2026
- U.S. locations
- 1
- States / cities
- Waco, Texas
- Conditions
- Chronic Kidney Disease, Anemia
- Interventions
- Roxadustat
- Drug
- Lead sponsor
- Kyntra Bio
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 145 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 35
- States / cities
- Mobile, Alabama • Pine Bluff, Arkansas • Azusa, California + 32 more
- Conditions
- Pain
- Interventions
- Buprenorphine, Morphine Sulfate
- Drug
- Lead sponsor
- Alameda Health System
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 122 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Oakland, California
- Conditions
- Advanced Recurrent Malignant Pleural Epithelioid Mesothelioma, Advanced Recurrent Malignant Peritoneal Epithelioid Mesothelioma, Advanced Recurrent Serous Ovarian Cancer, Advanced Pancreatic Ductal Adenocarcinoma (Optional, Dose Expansion, Not Initiated)
- Interventions
- BAY2287411
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 36 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2022
- U.S. locations
- 2
- States / cities
- Bethesda, Maryland • Houston, Texas
- Conditions
- Lymphoma
- Interventions
- Lenalidomide, Obinutuzumab, Cyclophosphamide, Doxorubicin, Vincristine, Prednisone
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2022
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Ovarian Cancer, Fallopian Tube Cancer, Peritoneal Carcinoma
- Interventions
- Pazopanib, Doxil
- Drug
- Lead sponsor
- SCRI Development Innovations, LLC
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2014
- U.S. locations
- 4
- States / cities
- Fort Myers, Florida • Orlando, Florida • Cincinnati, Ohio + 1 more
- Conditions
- Kidney Cancer, Melanoma (Skin)
- Interventions
- High-dose interleukin-2, genistein
- Biological · Dietary Supplement
- Lead sponsor
- Northwestern University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2014
- U.S. locations
- 1
- States / cities
- Chicago, Illinois
- Conditions
- Healthy Adult Subjects
- Interventions
- Complex oligosaccharide, Probiotic, PPI, H2 Blocker
- Dietary Supplement · Other
- Lead sponsor
- Prolacta Bioscience
- Industry
- Eligibility
- 18 Years to 44 Years
- Enrollment
- 62 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020
- U.S. locations
- 1
- States / cities
- Cypress, California
- Conditions
- B-cell Malignancy, Relapsed Cancer, Refractory Cancer, B-cell Lymphoma
- Interventions
- Tacabrutideg, Sonrotoclax, Zanubrutinib, Mosunetuzumab, Glofitamab, Obinutuzumab
- Drug
- Lead sponsor
- BeOne Medicines
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 80 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2029
- U.S. locations
- 17
- States / cities
- Phoenix, Arizona • Los Angeles, California • Jacksonville, Florida + 11 more
- Conditions
- Healthy
- Interventions
- PBI-4050 and midazolam
- Drug
- Lead sponsor
- Liminal BioSciences Ltd.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 22 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2018
- U.S. locations
- 1
- States / cities
- Tempe, Arizona
- Conditions
- Focus of the Study: Normal Volunteers
- Interventions
- Resveratrol, Resveratrol 2.5 grams x 1 dose and Piperine 5 mg x 1 dose, Resveratrol 2.5 grams x 1 dose and Piperine 25 mg x 1 dose
- Dietary Supplement
- Lead sponsor
- University of Wisconsin, Madison
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 24 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2011 – 2012
- U.S. locations
- 1
- States / cities
- Madison, Wisconsin